Search Results for “vaccine” – Page 9 – media

“National Key Laboratory for R&D of New Vaccines for Emerging Infectious Diseases” was launched!

On December 20, the kick-off meeting of “National Key Laboratory for R&D of New Vaccines for New Emerging Infectious Diseases” and the first meeting of the first Academic Committee were held at Sinopharm China Biologicals. Deng Jindong, Vice General Manager of Sinopharm and Chairman of China Bio, and Yang Xiaoming, Chief Scientist and Chief Engineer of Sinopharm, Chief Scientist of China Bio, and Director of the National Key Laboratory for R&D of Novel Vaccines for Newly Emerging Infectious Diseases, formally launched the “National Key Laboratory for R&D of Novel Vaccines for Newly Emerging Infectious Diseases”. Academician Zhao Jia, Academician Chen Xiangmei, Academician Li Zaikun, and Academician Wang Junzhi of the Chinese Academy of Engineering attended the launching meeting. After the launching meeting, the National Key Laboratory of New Vaccine Development for Emerging Infectious Diseases held the first meeting of the first academic committee. The Academic Committee listened to and passed ...
- Source: drugdu
- 87
- December 25, 2023
CanSino Bio and SPIMACO Signed a Cooperation Agreement on Innovative Vaccines, Continuing to Deepen the Comprehensive Strategic Partnership

Recently, China-Saudi Arabia Investment Conference was held in Beijing. As a representative of China’s innovative vaccine enterprises, CanSino Bio signed a vaccine cooperation framework agreement with SPIMACO, a Saudi Arabian pharmaceutical manufacturing company, at the Major Investment Collective Signing Ceremony, in which the two parties will cooperate in the commercialization of innovative vaccines, joint R&D and clinical research, as well as localized production. According to the agreement, the cooperation will focus on promoting the entry of CanSino Bio’s quadrivalent conjugate vaccine Manhexin® into Saudi Arabia and other markets in the Middle East and North Africa region. In Saudi Arabia, the quadrivalent conjugate vaccine has been included in the country’s childhood immunization program, and there is a strong demand for a quadrivalent conjugate vaccine with longer-lasting immunoprotection effect and higher safety in the local market. Post-marketing data shows that Mannhexin®, a quadrivalent conjugate vaccine from CanSino Bio, has a very impressive ...
- Source: drugdu
- 114
- December 20, 2023
AstraZeneca’s Icosavax M&A Deal Helps It Stand Out in Multivalent Vaccines Chase

AstraZeneca is acquiring Icosavax, which has technology well-suited for multivalent vaccines. Icosavax’s pipeline includes a Phase 3-ready program that protects against two pathogens that cause severe respiratory infections in older adults. By FRANK VINLUAN AstraZeneca is already in the respiratory syncytial virus market with two products, including the drug Beyfortus, approved earlier this year. An M&A deal will give AstraZeneca an RSV vaccine candidate based on technology that could help the company compete where new vaccines are going. AstraZeneca is acquiring clinical-stage Icosavax for $800 million up front, the pharmaceutical giant announced Tuesday. Under the deal terms, AstraZeneca will pay $15 for each Icosavax share, which is a nearly 43% premium to the stock’s closing price on Monday. AstraZeneca could pay an additional $5 per share depending on the progress of Icosavax’s vaccine candidates. That payout could bring the value of the deal to $1.1 billion. The vaccines of Seattle-based ...
- Source: drugdu
- 112
- December 14, 2023
CanSino Biologics completed the first subject enrollment in Phase I clinical trial of its component diphtheria-tetanus and pertussis combined vaccine for adolescents and adults

Recently, CanSino Biologics’ adsorbed acellular (component) diphtheria-tetanus combination vaccine (hereinafter referred to as “Tdcp for adolescents and adults”) officially launched Phase I clinical trials and completed the enrollment of the first subject. Tdcp for adolescents and adults is suitable for people aged 6 years and above. It is a booster vaccine for adolescents and adults. This randomized, blinded, controlled phase I clinical trial will initially evaluate the safety and immunogenicity of the vaccine. Whooping cough, diphtheria and tetanus, also known as diphtheria, are serious diseases caused by bacteria. Since the protective effect of immunity triggered by the main antigen of pertussis gradually decreases after vaccination, the incidence and mortality of pertussis gradually increase in the post-vaccination population. The domestic market is in urgent need of a DPT vaccine with longer-lasting immune protection and higher safety. Major developed countries have included this vaccine in their regular vaccination plans, but there is ...
- Source: drugdu
- 132
- December 14, 2023
CanSinoBIO Kicks-off the Polio VLP Vaccine Cooperation

December 1, 2023 – CanSino Biologics Inc. (“CanSinoBIO” or “the Company”) kicked off its innovative Polio VLP Vaccine Cooperation that aims to eradicate polio worldwide today as representatives from The Bill & Melinda Gates Foundation (the foundation) visited the facility. Dr. Xuefeng Yu, Chairman and CEO, Dr. Shoubai Chao, Chief Operating Officer, Dr. Tao Zhu, Chief Scientific Officer, and Ms. Jing Wang, Chief Commercial Officer and representatives from CanSinoBIO gave warm welcome to the foundation delegation. Dr. Xuefeng Yu expressed his gratitude to the foundation for their support over the past years that enabled CanSinoBIO to play a vital role in the global polio eradication efforts. CanSinoBIO is committed to continuously focusing on this fight against the vaccine-preventable disease and make a greater impact on global public health. CanSinoBIO has been actively participating in the World Health Organization (the WHO) polio eradication strategy to eliminate the disease, and has been ...
- Source: drugdu
- 86
- December 14, 2023
Announcement of New Coronavirus Variant mRNA Vaccine (Omicron XBB.1.5) Approved for Emergency Use

Walvax Biotechnology Co., Ltd. (hereinafter referred to as the “Company”), in cooperation with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co. (hereinafter referred to as the “RQ3033 Vaccine” or the “Vaccine”) developed by the Company in cooperation with Fudan University and Shanghai Blue Magpie Bio-pharmaceutical Company Limited (hereinafter referred to as the “Shanghai Blue Magpie”), which was approved by the relevant state departments for inclusion in the Emergency Use Program after receiving a letter from the Vaccine Research and Development Task Force of the State Council’s Research and Development Group of the Joint Prevention and Joint Control Mechanism on December 1, 2023 The “Vaccine” was approved for emergency use by the relevant state departments. The RQ3033 vaccine is an iterative vaccine developed on the basis of the mRNA technology platform jointly established by the Company, Fudan University and Shanghai Blue Magpie, and on the basis of the first-generation vaccine, i.e., ...
- Source: drugdu
- 110
- December 13, 2023
Announcement of Changchun BCHT Biotechnology Co. on Voluntary Disclosure of Approval of Clinical Trial Application for Freeze-dried Human Rabies Vaccine (Human Diploid Cells)

Important Notice: Changchun BCHT Biotechnology Co. (hereinafter referred to as the “Company”) has recently received the Notice of Approval of Drug Clinical Trial from the State Drug Administration. 2, the freeze-dried human rabies vaccine (human diploid cells) subsequent clinical trials are uncertain, and there is a certain degree of uncertainty whether the commercial purpose can ultimately be achieved. Investors are kindly advised to make decisions with caution and pay attention to the prevention of investment risks. The relevant information is announced as follows: I. Main information of the Notice of Approval of Drug Clinical Trial Acceptance No.: CXSL2300615 Notification No.: 2023LP02456 Drug Name: Lyophilized Human Rabies Vaccine (Human Diploid Cells) Conclusion: Agree to carry out clinical trials for the prevention of rabies. Approval date: December 6, 2023 The freeze-dried human rabies vaccine (human diploid cell) approved by the Company this time is freeze-dried human rabies vaccine (MRC-5 cell). II. Introduction ...
- Source: drugdu
- 100
- December 13, 2023
GSK Pulls Ahead of Pfizer in RSV Vaccine Market as Arexvy Nears Blockbuster Status

By Tristan Manalac Pictured: GSK building in Poznan, Poland/iStock, Wirestock GSK CEO Emma Walmsley on Thursday touted the smooth launch of its respiratory syncytial virus vaccine Arexvy and its strong potential for growth in the coming years. In an interview with Reuters, Walmsley said the British biopharma is “delighted” with the progress it has made in the RSV vaccine race with Pfizer. “We are delighted with the start of our RSV vaccine,” Walmsley said, adding that the company expects Arexvy “will be more than £1 billion in its first year, (it) has lots of headroom for growth.” GSK is positioning Arexvy to be its next blockbuster asset. The U.S. launch of the vaccine has so far reached three million of the more than 80 million adults over 60 at risk from RSV, according to Walmsley. Arexvy became the first FDA-approved RSV shot in May 2023 and is authorized for use ...
- Source: drugdu
- 109
- December 5, 2023
New WHO initiative to prioritise endemic pathogens for vaccine development

The World Health Organization (WHO) has commissioned 16 ‘Vaccine Value Profiles (VVPs)’ to prioritise key endemic pathogens to accelerate vaccine development. The VVPs are a result of collaboration between several pathogen and vaccine experts.Led by the Product Development and Research (PDR) team in WHO’s immunisation, vaccines and biologicals department, the aim of the VVPs is to advance the development of vaccines for pathogens that pose the biggest threat to public health and socio-economic burden, particularly in low- and middle-income countries. The forthcoming supplement in the journal Vaccine will feature the VVPs of 16 pathogens with vaccines in late-stage clinical development to provide comprehensive summaries of critical evidence to provide guidance for vaccine funding, research initiatives, and clinical and policy development strategies. They will comprise state-of-the art, publicly available data and information that highlights the current understanding of anticipated vaccine development, the implementation of feasibility studies and the public health impact ...
- Source: drugdu
- 173
- November 17, 2023
Valneva’s chikungunya vaccine approved by FDA for adults at increased exposure risk

Valneva’s chikungunya vaccine has been granted accelerated approval by the US Food and Drug Administration (FDA) for use in individuals ages 18 years and older who are at an increased risk of exposure to the mosquito-borne disease. The decision makes Ixchiq, which is administered as a single intramuscular injection, the world’s first licensed chikungunya vaccine. Chikungunya often causes sudden large outbreaks with high attack rates, affecting one-third to three-quarters of the population in areas where the virus is circulating. Infection leads to symptomatic disease in up to 97% of people after three to seven days following the mosquito bite, with clinical symptoms including fever, joint and muscle pain, headache, nausea and rash. “Infection with chikungunya virus can lead to severe disease and prolonged health problems, particularly for older adults and individuals with underlying medical conditions,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. He added: ...
- Source: drugdu
- 99
- November 14, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.